title: Fracture risk in men with congestive heart failure risk reduction with spironolactone.
abstract: OBJECTIVE
  The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF).
  
  
  BACKGROUND
  In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known.
  
  
  METHODS
  The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression.
  
  
  RESULTS
  We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324).
  
  
  CONCLUSIONS
  The use of spironolactone is inversely associated with fractures in men with CHF.
authors.affiliation: Department of Veterans Affairs Medical Center, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
authors.forename: Laura D
authors.initials: LD
authors.lastname: Carbone
authors.forename: Jessica D
authors.initials: JD
authors.lastname: Cross
authors.forename: Syed H
authors.initials: SH
authors.lastname: Raza
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Bush
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Sepanski
authors.forename: Saurabh
authors.initials: S
authors.lastname: Dhawan
authors.forename: Bilal Q
authors.initials: BQ
authors.lastname: Khan
authors.forename: Malini
authors.initials: M
authors.lastname: Gupta
authors.forename: Khurram
authors.initials: K
authors.lastname: Ahmad
authors.forename: Rami N
authors.initials: RN
authors.lastname: Khouzam
authors.forename: Dwight A
authors.initials: DA
authors.lastname: Dishmon
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Nesheiwat
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Hajjar
authors.forename: Waqas A
authors.initials: WA
authors.lastname: Chishti
authors.forename: Wael
authors.initials: W
authors.lastname: Nasser
authors.forename: Mehwish
authors.initials: M
authors.lastname: Khan
authors.forename: Catherine R
authors.initials: CR
authors.lastname: Womack
authors.forename: Tara
authors.initials: T
authors.lastname: Cho
authors.forename: Ashley R
authors.initials: AR
authors.lastname: Haskin
authors.forename: Karl T
authors.initials: KT
authors.lastname: Weber
mesh_terms: D000368:Aged; D050723:Fractures, Bone / Q000209:etiology*; D006333:Heart Failure / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D012189:Retrospective Studies; D013148:Spironolactone / Q000627:therapeutic use*
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone